Marking National Technology Day 2026, the Indian Council of Medical Research (ICMR) transferred three indigenous medical technologies to private industry partners. The announcement was made during the ‘विज्ञान–Tech’ programme at the BRIC–National Institute of Immunology, an event coordinated by the Office of the PSA that brought together 14 scientific ministries. These technology transfers, facilitated under ICMR’s Medical Innovations Patent Mitra initiative, are designed to translate publicly funded research into affordable, industry-ready healthcare solutions.
The licensed technologies address critical gaps in diagnostics for cancer, blood disorders, and viral fevers. Beyond these transfers, ICMR showcased high-impact innovations including Covaxin, a CRISPR-Cas-based TB detection system, and a Nipah point-of-care assay. A national compendium was also released featuring 25 additional ICMR innovations in medical devices and digital health, reinforcing the government’s "Whole-of-Government" approach to building a self-reliant, innovation-led healthcare ecosystem under the Viksit Bharat vision.
Key Technologies Transferred to Industry
Prostate Biopsy Guide (PSP94 ELISA): A cost-effective tool to help clinicians decide on biopsies for patients with specific PSA levels; licensed to Krishgen Labs Pvt. Ltd.
Coagulation Disorder Point-of-Care (POC): A diagnostic for Factor VIII inhibitors used in managing blood disorders; licensed to Meril Life Sciences.
Triple-Virus RT-PCR Kit: A single-tube multiplex test capable of detecting Dengue, Chikungunya, and Zika viruses simultaneously; licensed to Vanguard Life Sciences.
Exhibited Innovations: ICMR also highlighted its Biolarvicide for mosquito control and the COVID Kavach ELISA kit.
What is a "Point-of-Care (POC) Diagnostic"?
A Point-of-Care (POC) diagnostic is a medical test performed at or near the site of patient care, such as a clinic or a patient's home, rather than in a centralized laboratory. These tests provide rapid results, allowing for immediate clinical decisions. In the context of the ICMR technology transfer, the Factor VIII inhibitor diagnostic allows for quick monitoring of coagulation disorders, significantly reducing the waiting time for critical blood-related treatments and making specialised diagnostics accessible outside of major hospitals.
Policy Relevance
Accelerates "Make in Bharat": Licensing indigenous patents to domestic firms like Meril and Krishgen Labs strengthens India’s medical device manufacturing sector and reduces reliance on expensive imports.
Lowers Diagnostic Costs: The development of "cost-effective" tools, such as the PSP94 ELISA, ensures that advanced cancer screening becomes more affordable for the general population.
Enhances Pandemic Preparedness: The Triple-Virus RT-PCR kit allows for faster differential diagnosis during monsoon-related outbreaks of Dengue and Chikungunya, improving public health response times.
Strengthens IP Ecosystem: The use of the Medical Innovations Patent Mitra initiative demonstrates a structured pathway for protecting and commercializing intellectual property developed in public labs.
Fosters Multi-Sectoral Synergy: The ‘विज्ञान–Tech’ platform aligns with the Viksit Bharat 2047 goal of integrating government, academia, and industry to solve national health priorities.
Relevant Question for Policy Stakeholders: With ICMR successfully transferring three major patents to the private sector, how can the Department of Health Research standardise these 'Technology Transfer' protocols across all autonomous institutes to ensure that indigenous lab-scale innovations reach the mass market within 12–18 months?
Follow the Full News Here: CMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026